Environmental Exposure to Volatile Organic Compounds is Associated with Endothelial Injury

*Daniel W. Riggs,¹⁻⁵ *Marina V. Malovichko,¹⁻⁴ Hong Gao,¹⁻⁴ Katlyn E. McGraw,¹⁻⁴ Breandon S. Taylor,^{1,2} Tatiana Krivokhizhina,¹⁻⁴ Shesh N. Rai,^{1,2,6} Rachel J. Keith,^{1,2,4} Aruni Bhatnagar,¹⁻⁴ and Sanjay Srivastava¹⁻⁴

¹Superfund Research Center, University of Louisville; ²Diabetes and Obesity Center, University of Louisville; ³Christina Lee Brown Envirome Institute, University of Louisville; ⁴Division of Environmental Medicine, Department of Medicine, University of Louisville; ⁵Department of Epidemiology and Population Health, University of Louisville; ⁶Department of Bioinformatics and Biostatistics, University of Louisville

*These people contributed equally to the manuscript

Address correspondence to: Sanjay Srivastava, PhD
Superfund Research Center, Cardiovascular
Innovation Institute
302 E. Muhammad Ali Blvd
Louisville, KY 40202
Phone: 502-852-5724; Fax: 502-852-5834
E-mail: sanjay.srivastava@louisville.edu

ABSTRACT

Objective: Volatile organic compounds (VOCs) are airborne toxicants abundant in outdoor and indoor air. High levels of VOCs are also present at various Superfund and other hazardous waste sites; however, little is known about the cardiovascular effects of VOCs. We hypothesized that ambient exposure to VOCs exacerbate cardiovascular disease (CVD) risk by depleting circulating angiogenic cells (CACs).

Approach and Results: In this cross-sectional study, we recruited 603 participants with low-to-high CVD risk and measured 15 subpopulations of CACs by flow cytometry and 16 urinary metabolites of 12 VOCs by LC/MS/MS. Associations between CAC and VOC metabolite levels were examined using generalized linear models in the total sample, and separately in non-smokers. In single pollutant models, metabolites of ethylbenzene/styrene and xylene, were negatively associated with CAC levels in both the total sample, and in non-smokers. The metabolite of acrylonitrile was negatively associated with CD45^{dim}/CD146⁺/CD34⁺/AC133⁺ cells and CD45⁺/CD146⁺/AC133⁺, and the toluene metabolite with AC133⁺ cells. In analysis of non-smokers (n=375), multipollutant models showed a negative association with metabolites of ethylbenzene/styrene, benzene, and xylene with CD45^{dim}/CD146⁺/CD34⁺ cells, independent of other VOC metabolite levels. Cumulative VOC risk score showed a strong negative association with CD45^{dim}/CD146⁺/CD34⁺ cells, suggesting that total VOC exposure has a cumulative effect on pro-angiogenic cells. We found a non-linear relationship for benzene, which showed an increase in CAC levels at low, but depletion at higher levels of exposure. Sex and race, hypertension, and diabetes significantly modified VOC associated CAC depletion.

Conclusion: Low-level ambient exposure to VOCs is associated with CAC depletion, which could compromise endothelial repair and angiogenesis, and exacerbate CVD risk.

1. INTRODUCTION

Exposure to ambient air pollution has been widely recognized to be an important contributor to premature mortality and morbidity. The Global Burden of Disease (GBD) study estimates that in 2015, 4.2 million deaths could be attributed to ambient air pollutants, with an additional 2.8 million deaths due to household air pollution.¹ Exposure to fine particulate matter in the ambient air, defined as particle size < 2.5 µm in diameter (PM_{2.5}), is associated with an increased risk for hypertension,² myocardial infarction,³ type 2 diabetes,^{4,5} stroke,⁶ and cardiovascular mortality.⁷ The emphasis on PM_{2.5} and cardiovascular disease (CVD) has been motivated largely by the availability of historical monitoring data, however in an urban setting, over 90% of pollutant mass consists of gases or vaporous compounds, such as volatile organic compounds (VOCs).⁸ In comparison with PM_{2.5}, data on VOCs tend to exhibit higher temporal and spatial variability.

Most studies on VOC have focused on tobacco smoke⁹⁻¹¹ which represents a major source of human exposures. However, non-tobacco derived VOCs are ubiquitous in urban environments. High concentrations of VOCs such as alkanes, alkenes, aromatic hydrocarbons, and aldehydes, are emitted into the atmosphere from both anthropogenic and biogenic sources, and although biogenic VOCs are more abundant worldwide, in urban areas, anthropogenic VOCs are often higher.¹² Outdoor VOC exposures can originate from vehicle emissions, industrial facilities, landfills and hazardous waste sites, while indoor exposure can originate from diverse sources, such as paints, cleaning

agents, personal care products, and solvents.¹³ Our analysis of the secular trends of VOC exposures in the US suggests that even though there was a decline in the ambient air VOC levels, individual-level exposure increased from 2005-2014.¹⁴ Hence, there is urgent need to assess the health impacts of VOC exposures.

VOC exposure have been associated with a wide range of acute and chronic health effects, including allergies, respiratory diseases, liver dysfunction, and cancer.¹⁵ Moreover, exposures to ambient levels of acrolein, benzene, and xylene have been associated with elevated CVD risk.^{17, 18} In an intra-urban analysis of VOC gradients, higher levels of VOCs were found to be associated with increased cardiovascular and cancer mortality.¹⁶ Moreover, longitudinal time-series studies have shown that ambient VOCs, such as alkenes and alkynes, are associated with increased heart failure emergency hospitalizations,¹⁹ as well as overall cardiovascular hospitalizations,²⁰ and that occupational exposure to VOC such as styrene increases the relative risk of death from ischemic heart disease.²¹

The biological plausibility that VOCs can induce cardiovascular injury and exacerbate CVD is extensively supported by a range of animal studies showing that exposures to benzene, acrolein, and formaldehyde, can lead to changes in blood pressure regulation,²²⁻²⁴ depletion of circulating stem cells,²⁵ insulin resistance,²⁶ and platelet activation.²⁷ Exposure to these VOCs also induces systemic dyslipidemia, lipoprotein modification,²⁸ dilated cardiomyopathy;²⁹ and lead to the acceleration of atherogenesis³⁰ and exacerbation of myocardial ischemic injury.³¹ Nonetheless, despite this evidence, little is known about the effects of VOCs on the mechanisms and processes that contribute to cardiovascular disease in humans. Previous work has shown that in

humans, high levels of VOC exposures from sources such as cigarette smoke^{32, 33} and diesel exhaust³⁴ are associated with endothelial dysfunction. We have previously found that exposure to acrolein and 1,3-butadiene are associated with lower reactive hyperemia index, a measure of endothelial function.^{13, 35} The endothelium is a first line of defense of cardiovascular tissues against environmental toxins, and endothelial function is a sensitive reflection of vascular and systemic health. Therefore, to identify and understand the effects of VOC exposures and cardiovascular health, we measured circulating angiogenic cells (CAC), also referred to as endothelial progenitor cells (EPC). It is believed that these cell aid in the repair of the endothelium after injury, and are good biomarkers of vascular function.^{36, 37} CAC levels are associated with several CVD risk factors,³⁸ and are predictive of both cardiovascular events and cardiovascular mortality.³⁹ Thus, using CACs as surrogate biomarkers of endothelial health, we examined their association with urinary levels of VOC metabolite levels in participants with low to severe CVD risk.

2. METHODS

2.1 Study Population and Design

In a cross-sectional study, adult study participants, aged 25-70 years, were recruited from the Louisville, KY area. Recruitment occurred in the summer months (May to September) in the years 2018 and 2019, to minimize seasonal outdoor VOC heterogeneity. Persons unwilling or unable to provide informed consent or with significant and/or severe comorbidities were excluded. These included subjects that had hepatitis, HIV/AIDS, active treatment for cancer, and active bleeding including wounds. Other exclusions included subjects with body weight less than 100 pounds, pregnant women,

prisoners, and other vulnerable populations, those with conditions known to effect peripheral blood cell counts and bone marrow function.

At the time of enrollment non-fasting blood and spot urine were collected from patients who met the enrollment criteria and gave written consent. Demographic information, including age, sex, ethnicity, residential address, smoking status history and secondhand smoke exposure (verified by measurement of urinary cotinine concentrations), and BMI (calculated from self-reported height and weight) was obtained by using a questionnaire. Information on medication usage, blood pressure, and CVD history, including incidence of heart attack, heart failure, angina, hypertension, hypercholesterolemia, diabetes, obesity, stroke, and revascularization were also obtained through the questionnaire. For the current study, hypertension was defined as a previous diagnosis of hypertension or systolic blood pressure greater than 140 mmHg. Diabetes was defined as previous diagnosis of diabetes or HbA1C greater than 6.5. The study was approved by the University of Louisville Institutional Review Board (IRB 15.1260).

A total of 735 individuals met the inclusion criteria (Scheme 1).

Scheme 1. Recruitment flow chart.

Of those enrolled in the study, 115 individuals did not provide blood samples, or did not have circulating angiogenic cell measurements, 9 individuals did not provide urine samples, and 8 were missing other covariates. The final sample consisted of 603 participants with both urinary VOC metabolites and CAC measurements. For the non-smoker analysis, participants (n=228) with urinary cotinine value >40 µg/g creatinine were excluded, for a final sample size of n=375 participants.

2.2 Urinary Volatile Organic Compound Metabolites

Urinary metabolites of 12 VOCs (16 metabolites), and free forms of the nicotine metabolite cotinine were quantified by ultra-performance liquid chromatography-mass spectrometry (UPLC-MS/MS) as described before.^{9, 11, 40} All VOC metabolites that were below the limit of detection (LOD) were imputed with the LOD value divided by the square root of 2. All urinary analytes were normalized to urinary creatinine levels, measured on

a COBAS MIRA-plus analyzer (Roche, New Jersey) with Infinity Creatinine Reagent (Thermo Fisher Scientific, Massachusetts). A complete list of metabolites and parent compounds is provided in supplementary material (Table S1).

2.3 Circulating Angiogenic Cells

Fifteen different subtypes of circulating angiogenic cells were measured in the peripheral blood by flow cytometry - on fresh blood specimens as previously described.^{17, 41} CACs were defined as CD14 negative cells and differentiated into subtypes based on expression of CD45, CD34, CD146 and AC133 surface markers.

2.4 Air Pollution and Meteorological Data

Data on ambient levels of PM_{2.5} (particulate matter with an aerodynamic diameter of $\leq 2.5 \mu\text{m}$; $\mu\text{g}/\text{m}^3$) and ozone (ppm) were obtained from three regional EPA-validated monitoring stations in the Louisville, KY region. We used the average of the three monitors for the day the study participants provided blood and urine samples.

Data on average daily temperature ($^{\circ}\text{F}$) and relative humidity (%) were obtained from the National Oceanic and Atmospheric Administration's (NOAA) National Centers for Environmental Information. Data was download for the Louisville International Airport monitoring station, which is in close proximity to the study participants' residence, for the day the study participants provided blood and urine sample. This data is publicly available (<https://www.ncdc.noaa.gov/cdo-web/datatools/selectlocation>).

2.5 Statistical Analysis

Participant characteristics are expressed as mean $\pm$ standard deviation (SD) for continuous variables, and frequency (%) for categorical variables. Descriptive statistics

were conducted for all VOC metabolites. Because CACs were positive, and heavily right-skewed, generalized linear models with the gamma distribution and log-link were used to examine the association between CACs and VOC metabolites (Figure 1). Models used natural log-transformed VOC metabolites and were adjusted based on prior literature showing an association with VOC exposure or CAC levels.⁴¹⁻⁴⁷ Model adjustments for full data set included: age, sex, race, BMI, diabetes status, hypertension status, daily PM_{2.5} levels, and smoking status. There are a total of 240 unique comparisons between CACs and VOC metabolites. To account for multiple testing, we applied the Benjamini-Hochberg procedure to control the false-discovery rate (FDR).

Analysis of non-smokers

Models for non-smokers (urinary cotinine <40 µg/g creatinine) were adjusted for age, sex, race, BMI, diabetes status, hypertension status, and daily PM_{2.5} levels. Pearson correlations were performed across VOC metabolites and daily PM_{2.5}, ozone, temperature, and relative humidity (Supplemental Figure 1). We examined potential non-linear relationships between VOC metabolites and CACs using restricted cubic splines, with tests for non-linearity using the likelihood ratio test. An environmental risk score (ERS) representing cumulative VOC exposure risk was calculated for each CAC using a modified version of the method developed by Park *et al.*⁴⁸ Briefly, (1) VOC metabolites were log transformed, (2) each log-transformed VOC metabolite was regressed against each CAC separately, while adjusting for covariates, (3) the environmental risk score for each participant was calculated as the sum of log-transformed VOC metabolite x (regression coefficient/standard error). If multiple VOC metabolites came from the same parent compound, only one was used in the creation of the ERS. The final set of VOC

metabolites used to calculate the ERS consist of: 3HPMA, AAMA, CYMA, MU, MHBMA3, HPMMA, AMCC, PGA, 2HPMA, MA, BMA, and 3MHA+4MHA. Multi-pollutant models including all VOC metabolites that were independently associated with CACs were further developed to test whether single VOC effects were confounded by correlated VOCs (Pearson correlations provided in Supplemental Table 2). These models used log-transformed metabolite values, and the same adjustments as single pollutant models. Interactions between covariates and log VOC metabolites were tested in single pollutant models. We stratified analyses by participant characteristics to examine whether effect estimates differed by subgroups.

In addition to single-VOC models, we created models for multiple VOC exposures. To assess multiple VOC exposures as a mixture, we applied a Bayesian Kernel Machine Regression (BKMR) approach to flexibly model the relationship between the mixture of VOC metabolites and each of the 15 CACs.⁴⁹ The BKMR is a semi-parametric technique that models the exposure response relationship as a non-parametric kernel function of the mixture components, adjusting for covariates parametrically. Implementation of BKMR relied on a Gaussian kernel distribution, with flat priors. The Gaussian kernel flexibly captures underlying functional forms without specifying the shape of the exposure-response curve. This method can assess independent effects, estimate the overall mixture, and assess for interactions among mixture components. We used R software (version 4.0.2) and the bkmr package⁵⁰ to create posterior inclusion probabilities (PIPs) that quantify the relative importance of each exposure in the model, assess univariate and bivariate associations between mixture components and CACs, assess interactions

among VOC metabolites, and estimate the effect of the overall mixture on individual CACs.

As a sensitivity analysis, we conducted generalized linear models additionally adjusting one at a time for temperature or relative humidity, while adjusting for the covariates as above. We then repeated the models adjusting for ozone in place of PM_{2.5}, while adjusting one at time for temperature, then relative humidity. All statistical analyses were performed using SAS, version 9.4 (SAS Institute, Inc., Cary, North Carolina) and GraphPad Prism, version 8 (GraphPad Software, La Jolla, California).

3. RESULTS

The demographic characteristics of study participants are summarized in Table 1.

Table 1. Participant Characteristics

Variable	Total (n=603)	Non-Smokers (n=375)	Smokers (n=228)	p-value
Sex, Male	242 (40%)	135 (36%)	107 (47%)	0.008
Race				<0.001
White	464 (77%)	311 (83%)	153 (67%)	
Black	106 (18%)	43 (11%)	63 (28%)	
Other	33 (5%)	21 (6%)	12 (5%)	
Age (years)	49.7 ± 12.7	50.6 ± 13.2	48.3 ± 11.8	0.028
BMI (kg/m ²)	30.2 ± 6.8	30.7 ± 7.0	29.4 ± 6.4	0.023
SBP (mmHg)	127.9 ± 17.6	128.5 ± 18.1	127.1 ± 16.8	0.349
DBP (mmHg)	78.6 ± 11.4	78.1 ± 11.2	79.4 ± 11.8	0.178
Hypertension	247 (41%)	156 (42%)	91 (40%)	0.683
Diabetes	116 (19%)	65 (17%)	51 (22%)	0.128
MI	36 (6%)	24 (6%)	12 (5%)	0.632
Medication Use				
ASA	67 (12%)	46 (13%)	21 (10%)	0.295
Statin	82 (14%)	60 (17%)	22 (10%)	0.037
ACE or ARB	87 (15%)	63 (18%)	24 (11%)	0.047
Beta Blockers	53 (9%)	35 (10%)	18 (9%)	0.624

Values represent mean ± S.D. for continuous variables, and frequency (%) for categorical variables. P-values are based on t-test for continuous variables, and Chi-squared test for

237 categorical variables. Abbreviations: BMI indicates body mass index; SBP, systolic blood
238 pressure; DBP, diastolic blood pressure; MI, myocardial infarction; ASA, aspirin; ACE,
239 angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker.

240
241 Compared with non-smokers, current smokers were more likely to be male (47% vs.
242 36%), Black (28% vs. 11%), were of younger age, and have lower BMI. Although
243 cardiovascular risk factors (blood pressure, hypertension, diabetes) were similar between
244 the two groups, non-smokers were more likely to use statins, and ACE or ARB
245 medications. Within the 375 non-smoking participants of the study, the average age was
246 50.6 years. A majority were female (64%) and White (83%); 42% were hypertensive, and
247 17% diabetic. The urinary metabolites of VOCs measured in study participants are listed
248 in Table 2, along with their parent VOCs.

249 Table 2. Urinary levels of the major metabolites of volatile organic compounds (VOCs)
250 in study participants.

Parent Structure	VOC	Metabolite	Total Mean $\pm$ SD	Non-Smokers Mean $\pm$ SD	n (%) LOD	Smokers Mean $\pm$ SD	n (%) LOD
Acrolein	CEMA	200.1 $\pm$ 225.9	115.8 $\pm$ 117.0	42 (11.2%)	338.6 $\pm$ 286.0	7 (3.1%)
		3HPMA	879.3 $\pm$ 1228.2	341.5 $\pm$ 344.6	0 (0%)	1763.7 $\pm$ 1594.1	0 (0%)
Acrylamide	AAMA	109.9 $\pm$ 120.3	72.4 $\pm$ 61.6	1 (0.3%)	171.5 $\pm$ 161.2	0 (0%)
Acrylonitrile	CYMA	60.9 $\pm$ 111.0	5.7 $\pm$ 17.2	231 (61.6%)	151.8 $\pm$ 137.4	7 (3.1%)
Benzene	MU	146.0 $\pm$ 195.7	133.4 $\pm$ 214.0	6 (1.6%)	166.8 $\pm$ 159.5	4 (1.8%)
1,3-Butadiene	DHBMA	405.7 $\pm$ 215.7	353.6 $\pm$ 175.9	0 (0%)	491.2 $\pm$ 246.2	0 (0%)
		MHBMA3	28.7 $\pm$ 39.8	9.1 $\pm$ 8.2	18 (4.8%)	60.8 $\pm$ 49.3	1 (0.4%)
Crotonaldehyde	HPMMA	623.0 $\pm$ 673.6	300.0 $\pm$ 255.2	1 (0.3%)	1223.9 $\pm$ 789.2	0 (0%)
N,N-Dimethylformamide	AMCC	299.2 $\pm$ 296.0	160.4 $\pm$ 117.3	5 (1.3%)	527.5 $\pm$ 354.3	0 (0%)

Ethylbenzene, styrene	PGA	302.9 ± 217.6	225.9 ± 145.5	11 (2.9%)	428.9 ± 254.6	3 (1.3%)
Propylene oxide	2HPMA	82.9 ± 355.9	58.4 ± 122.9	4 (1.1%)	123.3 ± 555.4	1 (0.4%)
Styrene, ethylbenzene	PHEMA	2.8 ± 4.1	2.2 ± 4.1	174 (46.4%)	3.9 ± 4.0	37 (16.2%)
		MA	323.0 ± 253.6	232.8 ± 165.5	1 (0.3%)	470.4 ± 299.9	0 (0%)
Toluene	BMA	11.7 ± 12.4	11.5 ± 12.1	4 (1.1%)	11.9 ± 12.9	0 (0%)
Xylene	2MHA	54.7 ± 85.5	30.1 ± 53.4	53 (14.1%)	95.0 ± 109.5	6 (2.6%)
		3MHA+4MHA	405.9 ± 539.9	194.9 ± 303.1	30 (8.0%)	750.9 ± 653.4	3 (1.3%)

251 VOC metabolites were measured in 375 non-smoking participants, 25-70 years of age with low
 252 to severe CVD risk. IQR, interquartile range; LOD, limit of detection. Units: µg/g creatinine. The
 253 complete chemical names of each metabolite are listed in Supplemental Table 1.

254
 255 VOC metabolites had a high degree of variability in both smokers and non-smokers.
 256 Participants who were defined as current smokers consistently showed higher average
 257 VOC metabolite levels than non-smokers. Although significant levels of most VOC
 258 metabolites could be detected in non-smokers, in many (>20%) samples the level of
 259 acrylonitrile (CYMA), styrene/ethylbenzene (PHEMA) metabolites were below the limit of
 260 detection (LOD).

261 In single-VOC analysis, the levels of several urinary VOC metabolites were
 262 associated with the levels of CACs measured in peripheral blood (Figure 1). In the full
 263 data set, PGA was significantly associated with CAC-3, 5, 6, and 15, MU was significantly
 264 associated with CAC-10, and BMA was associated with CAC-5. Additionally, we found
 265 that CAC-3 was associated with CYMA, PHEMA, 2-MHA, and 3-MHA+4-MHA,
 266 suggesting that CAC-3 may be a sensitive marker to tobacco derived VOCs.

267

Figure 1. Association between the urinary metabolites of VOCs and circulating levels of CACs and heat map of p-values for pair-wise associations between the urinary metabolites of VOCs and circulating levels of CACs. (A) False Discovery rate adjusted p-values for total sample (n=603). (B) False Discovery rate adjusted p-values for non-smokers (n=375). Black grids represent positive associations and blue grids represent negative associations. The intensity of color represents p-values, with darker grids indicating smaller p-values. (C) The X axis represents % difference (± 95% confidence interval) per 2-fold increase in VOC metabolite for each CAC sub-population (CAC 1-15) in non-smokers (n=375). Generalized linear models were adjusted for

age, sex, race, BMI, diabetes, hypertension, and daily PM_{2.5} levels. Models for the full sample were additionally adjusted for smoking status.

Abbreviations: CEMA, N-Acetyl-S-(2-carboxyethyl)-L-cysteine; 3-HPMA, N-Acetyl-S-(3-hydroxypropyl)-L-cysteine; AAMA, N-Acetyl-S-(2-carbamoylethyl)-L-cysteine; CYMA, N-Acetyl-S-(2-cyanoethyl)-L-cysteine; MU, *trans*, *trans*-muconic acid; DHBMA, N-Acetyl-S-(3,4-dihydroxybutyl)-L-cysteine; MHBMA3, N-Acetyl-S-(4-hydroxy-2-buten-1-yl)-L-cysteine; HPMA, N-Acetyl-S-(3-hydroxypropyl-1-methyl)-L-cysteine; AMCC, N-Acetyl-S-(N-methylcarbamoyl)-L-cysteine; PGA, Phenylglyoxylic acid; 2HPMA, N-Acetyl-S-(2-hydroxypropyl)-L-cysteine; PHEMA, N-Acetyl-S-(1-phenyl-2-hydroxyethyl)-L-cysteine +; MA, Mandelic Acid; BMA, N-Acetyl-S-(benzyl)-L-cysteine; 2MHA, 2-Methylhippuric acid; 3MHA+4MHA, 3-Methylhippuric acid + 4-Methylhippuric acid. * Represents significant association.

Analysis of non-smokers

In our analysis of non-smokers (Figure 1B, 1C), we found similar associations as in our analysis of the total sample. In non-smokers, some of the most pronounced effects were observed with PGA – a metabolite that could be derived from either ethylbenzene or styrene - which showed a significant inverse association with CACs-1,2,3,4,5,6, and 7, as well as CAC-13 and CAC-15. Several other VOC metabolites showed similar, but variable associations. The percent difference ranged from -10.7% (95% CI: -19.6%, -0.8%) to -42.8% (95% CI: -53.1%, -30.1%). Many VOC metabolites were inversely associated with CAC levels, including metabolites of xylene (3-MHA+4-MHA), acrylonitrile (CYMA), and 1,3-butadiene (MHBMA3). For benzene (MU), we observed a significant inverse association with CAC-1 (-11.9%; 95% CI: -20.0%, -3.0%), and its subpopulation CAC-7 (-10.7%; 95% CI: -18.3%, -2.3%), along with a positive association with CAC-10. Positive associations were also observed with toluene (BMA) and CAC-5, 11, 13, and 14, which share AC133⁺ marker. After correcting for multiple testing, PGA showed statistically significant associations with CAC-1, 3, 5, 6, and 15 (Figure 1B). Further, MU remained significantly associated with CAC-10 and BMA remained significantly associated with CAC-5.

In our sensitivity analysis of non-smokers, additionally adjusting temperature, relative humidity, and ambient ozone did not substantially alter our associations (Supplemental Figure 2). Overall, these observations suggest that exposure to several VOCs is generally associated with lower levels of several CAC subpopulations in peripheral blood, particularly the early progenitor CACs.

Because we found similar associations between CACs and VOCs in the total sample, and in non-smokers, we focused the rest of our analysis on the subgroup of non-smokers, to determine how low levels of VOCs are associated with endothelial damage. In non-smokers, there was minimal correlation between VOC metabolites and average daily ambient PM_{2.5}, ozone, temperature, and relative humidity (Supplemental Figure 1). The levels of urinary VOC metabolites showed a strong dependence on demographics. A comparison of urinary metabolites showed that females had higher levels of the metabolites of N,N'-DMF (AMCC), ethylbenzene/styrene (phenylglyoxylic acid, PGA and mandelic acid, MA) and toluene (BMA) than males. Likewise, in comparison with Blacks, Whites had higher levels of metabolites of benzene (*trans, trans*-muconic acid, MU), N,N'-DMF (N-Acetyl-S-(N-methylcarbamoyl)-L-cysteine, AMCC) and styrene/ethylbenzene (MA). The metabolites of several VOCs – 1,3, butadiene (N-Acetyl-S-(3,4-dihydroxybutyl)-L-cysteine, DHBMA), crotonaldehyde (N-Acetyl-S-(3-hydroxypropyl-1-methyl)-L-cysteine, HPMMA), N,N'-DMF (AMCC), styrene/ethylbenzene (MA), toluene (BMA), and xylene (3MHA+4MHA) were also higher in those >55 years of age. Urinary levels of the metabolite of butadiene (MHBMA3) and toluene (N-Acetyl-S-(benzyl)-L-cysteine, BMA and, 2-Methylhippuric acid, 2MHA) levels were higher in those with a BMI of <30 (Supplemental Table 2), reflecting different levels of exposure.

To determine the extent to which total VOC exposure can affect CAC levels, and which cell populations contribute to the directionality of the associations (found in Figure 1) we created an Environmental Risk Score (ERS) for each cell population (Figure 2).

Figure 2. Association between Environmental Risk Scores and Circulating Angiogenic Cells in non-smokers. Environmental Risk score was calculated for each cell population as follows: 1. The urinary levels of VOC metabolites were log transformed. 2. Each log transformed VOC metabolite level was regressed against the levels of the cells separately, while adjusting for covariates. 3. ERS was calculated as the sum of the log transformed VOC metabolite levels x (regression coefficient/standard error). Mean and standard deviation of the ERS was calculated for each CAC. Values are mean ± SD of environmental risk score for each cell population.

We found a strong negative risk score for CAC-1 (-62.9), CAC-3 (-54.6), and CAC-7 (-62.1), which are a related group of cells with common markers CD45^{dim}/CD146⁺/CD34⁺. To a lesser extent, we also found negative risk scores for CAC-6 (-47.6), and CAC-9 (-37.7), which are CD34⁺ cells. In comparison, we found positive

336 risk scores for CD45⁺ cells (CAC-12), along with subgroups of CD45⁺ cells: CAC-2, CAC-
337 8, and CAC-14. Moreover, we also found a positive score for CAC-10, which is CD146⁺.
338 This indicates that the levels of CD45⁺ cells were positively associated with the urinary
339 metabolites of VOC metabolites, whereas CD45^{dim} and CD34⁺ cells were negatively
340 associated with the metabolite levels.

341 We used restricted cubic splines to determine whether the relationship between
342 VOC metabolites and CACs was non-linear (Figure 3).

Figure 3. Exposure-response relationships between selected CACs and VOCs in non-smokers. Non-linear relationships between MU metabolites and CACs (**A**); VOCs and CAC-4 (**B**); and VOCs and CAC-8 (**C**) were examined using restricted cubic splines. Tests for non-linearity used the likelihood ratio test. Models are adjusted for age, sex, race, BMI, diabetes, hypertension, beta-blocker use, and daily PM_{2.5} levels. P-value represents likelihood ratio test for non-linearity.

We observed non-linear relationships between the circulating levels of several cell populations and the metabolite of benzene (MU). In general, low levels of MU was associated with higher levels of circulating cells, whereas higher MU levels were

associated with lower cell levels. These non-linear relationships are presented in Figure 3A, which shows a near significant ($p < 0.1$) non-linear relationships with CD146⁺ cell populations (CAC-2, 4, 5, and 6), and with AC133⁺ cell population – CAC-4 and CAC-5.

To determine whether AC133⁺ cells contribute to the non-linear relationships, we examined the association of subgroups of CD146⁺ cells, CAC-4 (CD45⁺/CD146⁺/AC133⁺) and CAC-8 (CD45⁺/CD146⁺/AC133⁻) with VOC metabolites. We found near significant ($p < 0.1$) non-linear relationships between CAC-4 and metabolites of acrolein, 1,3-butadiene, N, N-dimethylformamide, propylene oxide, ethylbenzene/styrene, and xylene. These non-linear relationships were not observed with CAC-8, with the exception of xylene (3-MHA+4-MHA), suggesting that early progenitor endothelial cells (CD146⁺/AC133⁺) are recruited at low exposure levels, but are depleted at high VOC exposures.

Given that co-exposure to VOCs is common, we used multi-VOC models to assess whether the significant VOC effects found in single-VOC models were confounded by co-exposures to other VOCs (Figure 4).

Figure 4. Association between circulating angiogenic cells and multiple VOCs in the same model (non-smokers). Values represent % difference per 2-fold increase in VOC metabolite. VOC metabolites are ordered by strength of their regression coefficients. Only significant metabolites from one-pollutant models were entered in the model. Models adjusted for age, sex, race, BMI, diabetes, hypertension, and daily PM_{2.5} levels.

For this analysis, we focused on rare cell populations with negative ERS scores CAC-3, CAC-5, CAC-7, and CAC-13 (Figure 2). We observed that the metabolite of ethylbenzene/styrene (PGA) remained negatively associated with CAC-3 (-37.0% per 2-fold increase; 95% CI: -48.7%, -22.6%), CAC-5 (-29.8%; 95% CI: -40.6%, -17.0%), CAC-7 (-16.8%; 95% CI: -29.1%, -2.4%), and CAC-13 (-13.1%; 95% CI: -22.2%, -2.8%), suggesting that the associations between PGA and CACs are independent of other VOC metabolite levels. We also found that the metabolites of xylene (2MHA) remained negatively associated with CAC-3, crotonaldehyde (HPMMA) remained positively

associated with CAC-5, benzene (MU) remained negatively associated with CAC-7, and toluene (BMA) remained positively associated with CAC-13.

In our Bayesian kernel machine regression analysis, important VOC metabolites contributing to changes in CACs are indicated by high posterior inclusion probabilities (Table 3).

Table 3. Posterior inclusion probabilities of individual VOC metabolites in the BKMR model for 15 CACs.

VOC	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15
CEMA	0.53	0.09	0.64	0.74	0.00	0.03	0.49	0.03	0.36	0.00	0.00	0.00	0.11	0.42	0.41
3HPMA	0.43	0.26	0.62	0.68	0.00	0.02	0.54	0.16	0.50	0.13	0.30	0.00	0.15	0.45	0.35
AAMA	0.43	0.10	0.61	0.65	0.00	0.00	0.48	0.06	0.35	0.00	0.00	0.00	0.04	0.42	0.39
CYMA	0.47	0.05	0.68	0.68	0.00	0.01	0.52	0.05	0.38	0.00	0.07	0.00	0.08	0.42	0.34
MU	0.48	0.13	0.60	0.77	0.00	0.01	0.44	0.06	0.38	0.55	0.00	0.00	0.18	0.38	0.39
DHBMA	0.57	0.12	0.61	0.78	0.00	0.02	0.58	0.01	0.33	0.00	0.02	0.00	0.02	0.45	0.47
MHBMA3	0.47	0.10	0.61	0.78	0.01	0.00	0.50	0.01	0.51	0.00	0.00	0.00	0.33	0.35	0.33
HPMMA	0.46	0.14	0.59	0.74	0.01	0.06	0.50	0.01	0.46	0.03	0.01	0.00	0.03	0.36	0.35
AMCC	0.50	0.10	0.57	0.70	0.03	0.01	0.58	0.03	0.35	0.00	0.03	0.00	0.08	0.46	0.39
PGA	0.54	0.19	0.64	0.62	0.03	0.02	0.80	0.03	0.26	0.00	0.02	0.00	0.04	0.44	0.44
2HPMA	0.43	0.17	0.61	0.70	0.00	0.01	0.53	0.04	0.30	0.02	0.05	0.00	0.04	0.37	0.35
PHEMA	0.47	0.07	0.65	0.61	0.01	0.15	0.49	0.05	0.40	0.03	0.00	0.00	0.06	0.40	0.34
MA	0.55	0.12	0.72	0.73	0.02	0.02	0.53	0.04	0.45	0.00	0.00	0.00	0.07	0.49	0.35
BMA	0.42	0.10	0.61	0.71	0.00	0.00	0.46	0.02	0.37	0.01	0.02	0.00	0.91	0.57	0.35
2MHA	0.53	0.19	0.76	0.76	0.02	0.00	0.74	0.02	0.38	0.00	0.06	0.00	0.09	0.34	0.41
3MHA+4MHA	0.46	0.10	0.62	0.89	0.12	0.03	0.71	0.01	0.30	0.00	0.01	0.00	0.05	0.44	0.37

Models (n=375) were adjusted for age, sex, race, BMI, diabetes, hypertension, and daily PM_{2.5} levels.

The directionalities of single VOC associations in our mixture models were generally consistent with the observed directionalities in our single VOC generalized linear models. For example, in mixture models, individuals with greater PGA levels had lower numbers of CACs, while individuals with greater BMA and HPMMA levels had higher numbers of CACs. As evident in Figure 5, we also found that the mixture of VOCs had a nonlinear relationship with CAC-4, similar to the nonlinear associations observed in our single VOC

models. We also found that greater exposure to the VOC mixture was associated with higher CAC-10 levels (Figure 5).

Figure 5. Overall association of the VOC metabolite mixture (and 95% credible intervals) with selected CACs, when all exposures are set to a given percentile relative to median. Models (non-smokers; n=375) were adjusted for age, sex, race, BMI, diabetes, hypertension, and daily PM_{2.5} levels.

The effect of the VOC mixture on CAC-10 was largely driven by benzene (MU), with a posterior inclusion probability of 0.55, where all other VOC metabolites were less than 0.15. We found minimal evidence of interactions between pairs of VOC metabolites in our mixture analysis (data not shown).

Because the metabolites of benzene, 1,3-butadiene, N,N-dimethylformamide, and ethylbenzene/styrene consistently showed strong associations with CACs, we investigated whether these associations were modified by the demographic characteristics of the participants or their co-morbidity profile. In our subgroup analysis,

we found a common theme in many of the models, in which participants who were male, White, normotensive, and recruited on low PM_{2.5} days showed stronger inverse relationships between VOCs and CAC levels (Figure 6).

Figure 6. Subgroup analysis of the relationship between different CAC population with the urinary metabolites of benzene (MU), 1,3-butadiene (MHBMA3), ethylbenzene/styrene (PGA), and N,N-Dimethylformamide (AMCC) in non-smokers. Generalized linear models were adjusted for

covariates - age, sex, race, BMI, diabetes, hypertension, and daily $PM_{2.5}$ levels, unless the covariates were used for stratification. *Significant interaction between subgroups in the full model.

For example, for CAC-13, we found a negative association between ethylbenzene/styrene metabolite (PGA) in White participants of -17.2% per 2-fold increase in CAC levels (95% CI: -26.4%, -7.0%), whereas in Black participants, we found a positive association of 79.1% (95% CI: 23.7%, 159.3%). We observed a similar relationship for the metabolite of benzene (MU), when stratified by race; however, this may be due to lower levels of MU in urine samples from Black participants (62.2 $\mu\text{g/g}$ creatinine) than White participants (146.0 $\mu\text{g/g}$ creatinine), as presented in *Supplemental Table 2*.

We also found some evidence that age and BMI modify the relationships between VOCs and CAC levels, although the direction was not consistent in all models. Interestingly, in several of our models, we found stronger inverse associations between VOC metabolite and CACs in normotensives than hypertensives, and to a lesser extent, non-diabetics than diabetics, - conditions that are known to affect cell migration. For example, for CAC-5, we found a negative association with ethylbenzene/styrene metabolite (PGA) in non-diabetics of -28.2% per 2-fold increase, and with N,N-dimethylformamide (AMCC) in non-diabetics of -24.0% per 2-fold increase, while the relationships in diabetics were not significant. To determine whether these results were due to differential levels of VOC exposure between subgroups, we calculated average metabolite levels for each subgroup *Supplemental Table 2*. We found that levels of MU (benzene) and PGA (ethylbenzene and styrene) were higher in diabetics than non-

diabetes and were higher in hypertensive than normotensive individuals, although normotensive had higher levels of 2HPMA (propylene oxide).

4. DISCUSSION

The major findings of this study are that the urinary metabolites of several common VOCs, such as ethylbenzene/styrene, benzene, xylene, and 1,3-butadiene were negatively associated with circulating angiogenic cells. We found similar associations in non-smokers compared with the total sample containing smokers. For some VOCs, such as benzene, we observed that low levels of their metabolites were positively associated with an increase in CAC levels, whereas at high levels of exposure were associated with a significant decrease in CAC levels. Our environmental risk score identified that CAC-1, CAC-3, and CAC-7, with common cell markers CD45^{dim}/CD146⁺/CD34⁺, were the most sensitive to total VOC exposure. Our mixture analysis revealed that the total VOC metabolite mixture was positively associated with CD146⁺ cells. We also found sex, race, age, and hypertension to be effect modifiers of the some of the relationships between the levels of VOC metabolites and CACs. Taken together, these findings suggest that exposure to VOCs could lead to deficits in endothelial repair capacity in a dose-dependent manner, which vary with sex, race, and comorbidities. Given that low CAC levels are predictive of future cardiovascular events and death³⁹, these results support the notion that VOC exposure is associated with significant vascular injury independent of tobacco use, and therefore it may be an important environmental risk factor for CVD.

The potential cardiovascular effects of VOCs derived from tobacco smoke have been extensively studied.⁹⁻¹¹ We found similar associations between VOCs and CACs in our total sample containing smokers, compared with our subgroup of non-smokers. This

suggests that the effects of VOC exposure on CACs is independent of tobacco smoke exposure and is still present at environmentally low levels. We additionally found that several VOC metabolites were associated with CAC-3 in the total sample analysis. We have previously shown that low levels of CAC-3 is associated with higher prevalence of diabetes, higher HbA1c levels, and impaired vascular function.³⁷ This could be due to the higher levels of several VOC metabolites in the total sample, such as CYMA (acrylonitrile), and PHEMA (ethylbenzene/styrene), which are typically difficult to detect in non-smokers. In contrast, the cardiovascular effects of VOCs not derived from tobacco smoke have received scant attention. Nonetheless, in addition to tobacco smoke, automobile emissions, industrial facilities, hazardous waste sites, and household products are major sources of VOC emissions, and therefore, VOC exposures are common and frequent.¹³ In our study, we found significant levels of the VOC metabolites in the urine of non-smokers, indicating particularly high levels of exposure to acrolein, crotonaldehyde, and 1,3-butadiene, and acrylamide, as well as the BTEXS (benzene, toluene, ethylbenzene, xylene and styrene) group of VOCs, suggesting a contribution of both indoor and outdoor exposure. Specifically, we found that the CAC levels were particularly sensitive to metabolites of BTEXS compounds. We observed significant associations between CACs and urinary metabolite of benzene (3 CACs), toluene (4 CACs), ethylbenzene/styrene (9 CACs), and xylene (4 CACs).

Although exposure to BTEXS is common, little is known about their cardiovascular effects. A study from Hong Kong found that short term elevations in atmospheric levels of benzene and TEX (toluene, ethylbenzene, and xylene) was associated with increases in circulatory disease mortality by 5.8% and 3.5%,⁵¹ although in a study from Toronto, no

intra-urban variations in VOC levels were found be associated with cardiovascular disease mortality.¹⁶ Other BTEXS such as toluene, styrene, ethylbenzene, and xylenes have been also linked to a higher prevalence of CVD,⁵² and exposure to VOCs such as benzene, ethylbenzene, and styrene have also been found to be associated with higher odds of developing metabolic syndrome.⁵³ Along with these data, the results of our study, support the notion that exposure to VOC could have adverse cardiovascular consequences, potentially due to low-level vascular injury reflected by changes in CAC levels.

We found inverse associations between metabolites of acrylonitrile and 1, 3-butadiene and CACs. Although the cardiovascular effects of acrylonitrile are less well studied, exposure to 1,3-butadiene has been found to accelerate the formation of atherosclerotic lesions in animal models, and polymorphisms in phase II enzymes that metabolize 1,3-butadiene are associated with the development of atherosclerosis in humans.⁵⁴ Hence, our observation that urinary metabolites of 1,3-butadiene are associated with CAC levels suggest that the cardiovascular risk of exposure to this VOC may be in part due to depletion of early, progenitor cells, which aid in vascular repair and thereby can prevent the progression of atherosclerotic lesions. Therefore, our observations linking exposure to VOCs such as 1,3-butadiene to concurrent changes in CACs, not only provides a new biological basis for the cardiovascular effects of VOCs, independent of concurrent exposure to PM_{2.5}, but also provides new insights into their mechanism of toxicity.

In real world scenario, the urban air contains many different VOCs and therefore, we conducted multi-VOC models controlling for all significantly associated metabolites

from the single VOC models. In particular, we found that the urinary metabolite PGA remained significantly associated with the levels of CD45^{dim}/CD146⁺/CD34⁺ cells (CAC-3, CAC-7), AC133⁺/CD146⁺ cells (CAC-5), and AC133⁺/CD34⁺ cells (CAC-13). PGA is oxidized from mandelic acid (MA) by alcohol dehydrogenase, and both are considered the major urinary metabolites of styrene and ethylbenzene exposure.⁵⁵ Styrene is mainly used in the manufacturing of plastics, synthetic rubbers, and resins, and is the top released carcinogen in the United States,⁵⁶ while ethylbenzene is found naturally in coal tar and petroleum, and used in the manufacturing of styrene.⁵⁵ The primary route of exposure to styrene and ethylbenzene is through inhalation, contributing up to 99% of total exposure, with 1-2% from food consumption.⁵⁷ We found that the ethylbenzene/styrene metabolite - PGA, but not MA was negatively associated with CACs. This could be due to the chemical structure of PGA, which is a ketone, and is therefore, more reactive than the acid metabolite MA. This could also be representative of higher ethylbenzene/styrene exposure, which would affect the ratio of PGA to MA through an increase in alcohol dehydrogenase activity. The results of our multi-VOC analysis indicate that CACs may be particularly sensitive to ethylbenzene/styrene exposures.

We found that the negative association between the N,N-DMF metabolite (AMCC) and CACs was significantly stronger in normotensive participants than those with hypertension. Previous work has shown that hypertension is associated with lower CAC levels and that hypertension is a major independent predictor of impaired endothelial progenitor cell migration.⁵⁸ It has also been demonstrated that hypertension accelerates EPC senescence in both clinical and experimental settings.⁵⁹ These findings suggest

that because of the inherent susceptibility of CACs to hypertension, CACs in hypertensive participants may be more vulnerable to exposure to VOCs such as N,N-DMF. N,N-DMF is a commonly used solvent with wide industrial applications, and occupational exposure to high levels of N,N-DMF is associated with liver injury;⁶⁰ however, our observation that even ambient exposure to N,N-DMF is associated with vascular injury, suggests that there may be a high risk of hypertension and cardiovascular disease even with low-level exposures.

The observed association between VOC metabolites and diminished circulating angiogenic cells suggest that individuals exposed to VOCs may have a lower capacity to repair the endothelium. These effects of VOC exposure appear to be similar to those of other environmental pollutants, which are also associated with suppression of CAC levels. Previous work has shown that exposure to PM_{2.5} over a period of 24h to several weeks suppresses EPC levels,^{41, 61} and exposure to pollutants such as particulate nickel,⁶² acrolein¹⁷ and benzene¹⁸ have also been shown to reduce CAC levels. These observations suggest that pollutant exposure either depletes CAC levels in peripheral blood or interferes with the release from the bone marrow and the spleen. However, in contrast to such suppression, CAC levels are slightly elevated in individuals breathing coarse PM⁶³ or those living close to a major roadway.⁶⁴ This biphasic response is consistent with the dose-response relationships observed in the current study, which are indicative of increased CAC mobilization (to promote repair) at low levels of exposure, and CAC suppression at higher exposures.

Recently, we showed that living in areas of high vegetation is associated with increased levels of CD34⁺/CD45⁺/AC133⁺ CACs, but decreased

CD31⁺/CD34⁺/CD45^{dim}/AC133⁺ CACs, ⁶⁵ suggesting greenness may be protective against air pollution related health effects. Thus, it seems that low levels of toxicity could lead to increased recruitment of CAC into the peripheral blood, whereas high levels of exposure could suppress CAC recruitment and/or depleting CAC by increasing utilization. The directionality of the effects of exposure on CAC levels may also depend upon locus of injury, some exposures may prevent recruitment, while others may induce injury that stimulates recruitment. Regardless, our results with VOCs suggest that exposure to these chemicals suppresses CAC levels in peripheral blood, but further studies are required to determine whether this is due to decreased recruitment or increased utilization.

We found that several VOC metabolite levels were negatively associated with angiogenic cells (CD45^{dim}/CD146⁺/CD34⁺), but positively associated with hematopoietic endothelial cells (CD45⁺/CD146⁺), as evident from our environmental risk score results (Schematic 2).

Scheme 2. Gating Strategy for the Human Circulating Angiogenic Cells. Blue indicates negative environmental risk score; orange indicates positive environmental risk score.

In comparison with CD45^{dim} cells, CD45⁺ CACs are more primitive, with the potential to self-renew and differentiate into specialized cells that can control biological activities such as homeostasis and response to inflammation.⁶⁶ Additionally, the angiogenic cells are rare, and can be easily depleted when used in the repair of endothelial injury. Our exposure response curves are consistent with this notion that at low levels of VOC exposure, CD45⁺ cells have the ability to regenerate to repair endothelial injury, however at high VOC exposure, the injury surpasses the cells capacity to regenerate or the mobilization of these cells from depots such as the spleen or bone marrow is prevented. Consistent with this notion, results from our Bayesian kernel machine regression also found a nonlinear relationship with the mixture of VOCs and CAC-4 (CD45⁺/CD146⁺/AC133⁺). Further, we found that the mixture of VOC metabolites was

positively associated with CD146⁺ cells. These cells are thought to be mature cells which detach from the intimal monolayer after endothelial injury. Studies have shown an increased number of CD146⁺ cells in CVD, such as unstable angina, acute myocardial infarction, stroke, and diabetes.⁶⁷ Positive associations could also be due to the specific VOC exposure. We found primarily positive relationships between the toluene metabolite (BMA) and CACs. This could be reflective of the low level of toxicity of toluene in comparison to other VOCs.

The major strength of this study is the use of individual level data to assess exposure. Although, measurements of the urinary metabolites do not permit source assignment, they do provide an integrated measure to total exposure of an individual whether via inhalation, ingestion, or endogenous production. Hence, in linking exposure to outcome, such measurements provide a unique advantage as exposure-response could be concurrently evaluated in the same individual. Using this approach, we were able to assess association between exposure and a sensitive and robust measure of preclinical cardiovascular injury (CACs) which is predictive of CVD events and mortality. In our analysis, we also adjusted for exposure to PM_{2.5} and were able to apply a composite VOC risk score that could be used in future studies.

Our study also has some limitations. Because of the cross-sectional nature of the study, the associations found in this study cannot address causality. Longitudinal studies are needed to determine whether VOC exposures are associated with adverse clinical outcomes, and whether these outcomes are related to changes in CAC levels. Our study also has the potential for type I errors due to testing of multiple CACs and VOC metabolites. However, due to the correlation between VOC metabolites, and limited prior

research on VOC exposure and CVD, we did not adjust for multiple comparisons, to preserve our type II error, and identify potential VOC candidates for future studies. Moreover, we used spot urine collection from each individual to estimate VOC exposure. Although, it has been reported that the inter-day reproducibility for most urinary VOC metabolites is good to excellent.^{68, 69} Following exposure, many VOCs rapidly undergo biotransformation to generate metabolites that can conjugate with glutathione. Other enzymatic reactions remove glutamic acid and glycine to produce a cysteine conjugate, which is N-acetylated and excreted in the urine as mercapturic acid.¹³ It has also been shown that smoking one cigarette, which generates high levels of VOCs, is sufficient to immediately affect the levels of CACs.⁷⁰ Therefore, because VOC metabolites and CAC levels were concurrently measured, it is likely that the observed association represent consequences of recent exposure. Additionally, our urinary VOC metabolites were normalized to creatinine to account for dilution differences, which could introduce error that relates to the dependence of creatinine excretions due to muscle mass, physical activity, and kidney disease. Another limitation of our study is that most participants were, by study design, of older age and at increased risk of cardiovascular disease. Thus, our sample could represent a group of susceptible individuals, which may limit generalizability of our findings.

In conclusion, we showed that metabolites of several VOCs were negatively associated with circulating levels of CD45^{dim}/CD146⁺/CD34⁺ cells and the mixture of VOC metabolites was positively associated with CD146⁺ cells in the peripheral blood. These findings suggest that exposure to low ambient levels of VOCs could damage the endothelium, and deplete rare CACs or inhibit their recruitment, and thereby compromise

endothelial repair. Given the global burden of CVD, and the ubiquitous distribution of VOCs, it is imperative to further assess their contribution to CVD risk. Because several commonly used products, such as paints, self-care products, and glue, are important source of VOCs, and that there are several sources of indoor emissions (compressed wood, fire-retardants), this study raises the possibility that environmental exposure to VOCs may be an important determinant of CVD risk. Our work also underscores the need for greater awareness of the potential dangers of VOC exposure and heightened vigilance against such exposures. Future longitudinal and mechanistic studies are needed to confirm current findings. If substantiated, an association between VOC exposure and CVD risk could be included in estimates of CVD risk and appropriate limits and recommendations could be developed to reduce both ambient and indoor VOC exposures.

Source of Funding: This research was supported in part by NIH grants ES023716, ES029846, ES019217, HL149351, HL120163 and GM127607; and Jewish Heritage Foundation of Excellence grant GN190574L.

Acknowledgements: The authors would like to thank all the partners, members, and volunteers involved in the HEAL study.

The authors declare they have no actual or potential competing financial interests.

References

1. Cohen AJ, Brauer M, Burnett R, Anderson HR, Frostad J, Estep K, Balakrishnan K, Brunekreef B, Dandona L, Dandona R, Feigin V, Freedman G, Hubbell B, Jobling A, Kan H, Knibbs L, Liu Y, Martin R, Morawska L, Pope CA, Shin H, Straif K, Shaddick G, Thomas M, van Dingenen R, van Donkelaar A, Vos T, Murray CJL, Forouzanfar MH. Estimates and 25-year trends of the global burden of disease attributable to ambient air pollution: an analysis of data from the Global Burden of Diseases Study 2015. *The Lancet* 2017;**389**:1907-1918.
2. Yang B-Y, Qian Z, Howard SW, Vaughn MG, Fan S-J, Liu K-K, Dong G-H. Global association between ambient air pollution and blood pressure: A systematic review and meta-analysis. *Environmental Pollution* 2018;**235**:576-588.
3. Mustafić H, Jabre P, Caussin C, et al. Main air pollutants and myocardial infarction: A systematic review and meta-analysis. *Jama* 2012;**307**:713-721.
4. Brook RD, Cakmak S, Turner MC, Brook JR, Crouse DL, Peters PA, Van Donkelaar A, Villeneuve PJ, Brion O, Jerrett M. Long-term fine particulate matter exposure and mortality from diabetes mellitus in Canada. *Diabetes care* 2013;DC_122189.
5. Rajagopalan S, Brook RD. Air pollution and type 2 diabetes: mechanistic insights. *Diabetes* 2012;**61**:3037-3045.
6. Shah ASV, Lee KK, McAllister DA, Hunter A, Nair H, Whiteley W, Langrish JP, Newby DE, Mills NL. Short term exposure to air pollution and stroke: systematic review and meta-analysis. *BMJ* 2015;**350**.
7. Rajagopalan S, Al-Kindi SG, Brook RD. Air Pollution and Cardiovascular Disease: JACC State-of-the-Art Review. *Journal of the American College of Cardiology* 2018;**72**:2054-2070.
8. Brook RD, Rajagopalan S, Pope III CA, Brook JR, Bhatnagar A, Diez-Roux AV, Holguin F, Hong Y, Luepker RV, Mittleman MA. Particulate matter air pollution and cardiovascular disease: an update to the scientific statement from the American Heart Association. *Circulation* 2010;**121**:2331-2378.
9. Lorkiewicz P, Riggs DW, Keith RJ, Conklin DJ, Xie Z, Sutaria S, Lynch B, Srivastava S, Bhatnagar A. Comparison of Urinary Biomarkers of Exposure in Humans Using Electronic Cigarettes, Combustible Cigarettes, and Smokeless Tobacco. *Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco* 2019;**21**:1228-1238.
10. De Jesús VR, Bhandari D, Zhang L, Reese C, Capella K, Tevis D, Zhu W, Del Valle-Pinero AY, Lagaud G, Chang JT, van Bemmelen D, Kimmel HL, Sharma E, Goniewicz ML, Hyland A, Blount BC. Urinary Biomarkers of Exposure to Volatile Organic Compounds from the Population Assessment of Tobacco and Health Study Wave 1 (2013-2014). *International journal of environmental research and public health* 2020;**17**.
11. Keith RJ, Fetterman JL, Orimoloye OA, Dardari Z, Lorkiewicz PK, Hamburg NM, DeFilippis AP, Blaha MJ, Bhatnagar A. Characterization of Volatile Organic Compound Metabolites

- 696 in Cigarette Smokers, Electronic Nicotine Device Users, Dual Users, and Nonusers of
697 Tobacco. *Nicotine & tobacco research : official journal of the Society for Research on*
698 *Nicotine and Tobacco* 2020;**22**:264-272.
- 699 12. Atkinson R, Arey J. Atmospheric degradation of volatile organic compounds. *Chemical*
700 *reviews* 2003;**103**:4605-4638.
- 701 13. Li AJ, Pal VK, Kannan K. A review of environmental occurrence, toxicity, biotransformation
702 and biomonitoring of volatile organic compounds. *Environmental Chemistry and*
703 *Ecotoxicology* 2021.
- 704 14. Konkle SL, Zierold KM, Taylor KC, Riggs DW, Bhatnagar A. National secular trends in
705 ambient air volatile organic compound levels and biomarkers of exposure in the United
706 States. *Environ Res* 2020;**182**:108991.
- 707 15. Shuai J, Kim S, Ryu H, Park J, Lee CK, Kim GB, Ultra VU, Jr., Yang W. Health risk
708 assessment of volatile organic compounds exposure near Daegu dyeing industrial
709 complex in South Korea. *BMC public health* 2018;**18**:528.
- 710 16. Villeneuve PJ, Jerrett M, Su J, Burnett RT, Chen H, Brook J, Wheeler AJ, Cakmak S,
711 Goldberg MS. A cohort study of intra-urban variations in volatile organic compounds and
712 mortality, Toronto, Canada. *Environmental pollution (Barking, Essex : 1987)* 2013;**183**:30-
713 39.
- 714 17. DeJarnett N, Conklin DJ, Riggs DW, Myers JA, O'Toole TE, Hamzeh I, Wagner S, Chugh
715 A, Ramos KS, Srivastava S, Higdon D, Tollerud DJ, DeFilippis A, Becher C, Wyatt B,
716 McCracken J, Abplanalp W, Rai SN, Ciszewski T, Xie Z, Yeager R, Prabhu SD, Bhatnagar
717 A. Acrolein exposure is associated with increased cardiovascular disease risk. *J Am Heart*
718 *Assoc* 2014;**3**.
- 719 18. Abplanalp W, DeJarnett N, Riggs DW, Conklin DJ, McCracken JP, Srivastava S, Xie Z,
720 Rai S, Bhatnagar A, O'Toole TE. Benzene exposure is associated with cardiovascular
721 disease risk. *PLoS One* 2017;**12**:e0183602.
- 722 19. Ran J, Qiu H, Sun S, Yang A, Tian L. Are ambient volatile organic compounds
723 environmental stressors for heart failure? *Environmental Pollution* 2018;**242**:1810-1816.
- 724 20. Ye D, Klein M, Chang HH, Sarnat JA, Mulholland JA, Edgerton ES, Winkquist A, Tolbert
725 PE, Sarnat SE. Estimating Acute Cardiorespiratory Effects of Ambient Volatile Organic
726 Compounds. *Epidemiology* 2017;**28**:197-206.
- 727 21. Matanoski GM, Tao XG. Styrene exposure and ischemic heart disease: a case-cohort
728 study. *American journal of epidemiology* 2003;**158**:988-995.
- 729 22. Lynch J, Jin L, Richardson A, Jagatheesan G, Lorkiewicz P, Xie Z, Theis WS, Shirk G,
730 Malovichko MV, Bhatnagar A, Srivastava S, Conklin DJ. Acute and chronic vascular
731 effects of inhaled crotonaldehyde in mice: Role of TRPA1. *Toxicol Appl Pharmacol*
732 2020;**402**:115120.
- 733 23. Jin L, Jagatheesan G, Guo L, Nystoriak M, Malovichko M, Lorkiewicz P, Bhatnagar A,
734 Srivastava S, Conklin DJ. Formaldehyde Induces Mesenteric Artery Relaxation via a

- 735 Sensitive Transient Receptor Potential Ankyrin-1 (TRPA1) and Endothelium-Dependent
736 Mechanism: Potential Role in Postprandial Hyperemia. *Front Physiol* 2019;**10**:277.
- 737 24. Awe SO, Adeagbo AS, D'Souza SE, Bhatnagar A, Conklin DJ. Acrolein induces
738 vasodilatation of rodent mesenteric bed via an EDHF-dependent mechanism. *Toxicol Appl*
739 *Pharmacol* 2006;**217**:266-276.
- 740 25. Conklin DJ, Malovichko MV, Zeller I, Das TP, Krivokhizhina TV, Lynch BH, Lorkiewicz P,
741 Agarwal A, Wickramasinghe N, Haberzettl P, Sithu SD, Shah J, O'Toole TE, Rai SN,
742 Bhatnagar A, Srivastava S. Biomarkers of Chronic Acrolein Inhalation Exposure in Mice:
743 Implications for Tobacco Product-Induced Toxicity. *Toxicol Sci* 2017;**158**:263-274.
- 744 26. Abplanalp WT, Wickramasinghe NS, Sithu SD, Conklin DJ, Xie Z, Bhatnagar A, Srivastava
745 S, O'Toole TE. Benzene Exposure Induces Insulin Resistance in Mice. *Toxicol Sci*
746 2019;**167**:426-437.
- 747 27. Sithu SD, Srivastava S, Siddiqui MA, Vladyskovskaya E, Riggs DW, Conklin DJ, Haberzettl
748 P, O'Toole TE, Bhatnagar A, D'Souza SE. Exposure to acrolein by inhalation causes
749 platelet activation. *Toxicol Appl Pharmacol* 2010;**248**:100-110.
- 750 28. Conklin DJ, Barski OA, Lesgards JF, Juvan P, Rezen T, Rozman D, Prough RA,
751 Vladyskovskaya E, Liu S, Srivastava S, Bhatnagar A. Acrolein consumption induces
752 systemic dyslipidemia and lipoprotein modification. *Toxicol Appl Pharmacol* 2010;**243**:1-
753 12.
- 754 29. Ismahil MA, Hamid T, Haberzettl P, Gu Y, Chandrasekar B, Srivastava S, Bhatnagar A,
755 Prabhu SD. Chronic oral exposure to the aldehyde pollutant acrolein induces dilated
756 cardiomyopathy. *Am J Physiol Heart Circ Physiol* 2011;**301**:H2050-2060.
- 757 30. Srivastava S, Sithu SD, Vladyskovskaya E, Haberzettl P, Hoetker DJ, Siddiqui MA, Conklin
758 DJ, D'Souza SE, Bhatnagar A. Oral exposure to acrolein exacerbates atherosclerosis in
759 apoE-null mice. *Atherosclerosis* 2011;**215**:301-308.
- 760 31. Wang GW, Guo Y, Vondriska TM, Zhang J, Zhang S, Tsai LL, Zong NC, Bolli R, Bhatnagar
761 A, Prabhu SD. Acrolein consumption exacerbates myocardial ischemic injury and blocks
762 nitric oxide-induced PKCepsilon signaling and cardioprotection. *J Mol Cell Cardiol*
763 2008;**44**:1016-1022.
- 764 32. Heitzer T, Ylä-Herttuala S, Luoma J, Kurz S, Münzel T, Just Hr, Olschewski M, Drexler H.
765 Cigarette smoking potentiates endothelial dysfunction of forearm resistance vessels in
766 patients with hypercholesterolemia: role of oxidized LDL. *Circulation* 1996;**93**:1346-1353.
- 767 33. Pittilo M. Cigarette smoking, endothelial injury and cardiovascular disease. *International*
768 *Journal of Experimental Pathology* 2000;**81**:219-230.
- 769 34. Törnqvist H, Mills NL, Gonzalez M, Miller MR, Robinson SD, Megson IL, MacNee W,
770 Donaldson K, Söderberg S, Newby DE, Sandström T, Blomberg A. Persistent Endothelial
771 Dysfunction in Humans after Diesel Exhaust Inhalation. *American journal of respiratory*
772 *and critical care medicine* 2007;**176**:395-400.

- 773 35. McGraw KE, Riggs DW, Rai S, Navas-Acien A, Xie Z, Lorkiewicz P, Lynch J, Zafar N,
774 Krishnasamy S, Taylor KC, Conklin DJ, DeFilippis AP, Srivastava S, Bhatnagar A.
775 Exposure to volatile organic compounds – acrolein, 1,3-butadiene, and crotonaldehyde –
776 is associated with vascular dysfunction. *Environmental research* 2021;**196**:110903.
- 777 36. Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, Quyyumi AA, Finkel T.
778 Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. *New*
779 *England Journal of Medicine* 2003;**348**:593-600.
- 780 37. Zafar N, Krishnasamy SS, Shah J, Rai SN, Riggs DW, Bhatnagar A, O'Toole TE.
781 Circulating angiogenic stem cells in type 2 diabetes are associated with glycemic control
782 and endothelial dysfunction. *PloS one* 2018;**13**:e0205851.
- 783 38. Werner N, Nickenig G. Influence of cardiovascular risk factors on endothelial progenitor
784 cells: limitations for therapy? *Arteriosclerosis, thrombosis, and vascular biology*
785 2006;**26**:257-266.
- 786 39. Werner N, Kosiol S, Schiegl T, Ahlers P, Walenta K, Link A, Böhm M, Nickenig G.
787 Circulating endothelial progenitor cells and cardiovascular outcomes. *New England*
788 *Journal of Medicine* 2005;**353**:999-1007.
- 789 40. Yeager R, Riggs DW, DeJarnett N, Srivastava S, Lorkiewicz P, Xie Z, Krivokhizhina T,
790 Keith RJ, Srivastava S, Browning M, Zafar N, Krishnasamy S, DeFilippis A, Turner J, Rai
791 SN, Bhatnagar A. Association between residential greenness and exposure to volatile
792 organic compounds. *The Science of the total environment* 2020;**707**:135435.
- 793 41. O'Toole TE, Hellmann J, Wheat L, Haberzettl P, Lee J, Conklin DJ, Bhatnagar A, Pope
794 CA, 3rd. Episodic exposure to fine particulate air pollution decreases circulating levels of
795 endothelial progenitor cells. *Circ Res* 2010;**107**:200-203.
- 796 42. Fadini GP, de Kreutzenberg S, Albiero M, Coracina A, Pagnin E, Baesso I, Cignarella A,
797 Bolego C, Plebani M, Nardelli GB. Gender differences in endothelial progenitor cells and
798 cardiovascular risk profile: the role of female estrogens. *Arteriosclerosis, thrombosis, and*
799 *vascular biology* 2008;**28**:997-1004.
- 800 43. Xia WH, Yang Z, Xu SY, Chen L, Zhang XY, Li J, Liu X, Qiu YX, Shuai XT, Tao J. Age-
801 Related Decline in Reendothelialization Capacity of Human Endothelial Progenitor Cells
802 Is Restored by Shear Stress. *Hypertension* 2012;**59**:1225-1231.
- 803 44. Samman Tahhan A, Hammadah M, Kelli HM, Kim JH, Sandesara PB, Alkhoder A, Kaseer
804 B, Gafeer MM, Topel M, Hayek SS, O'Neal WT, Obideen M, Ko Y-A, Liu C, Hesaroieh I,
805 Mahar E, Vaccarino V, Waller EK, Quyyumi AA. Circulating Progenitor Cells and Racial
806 Differences. *Circulation research* 2018;**123**:467-476.
- 807 45. Tobler K, Freudenthaler A, Baumgartner-Parzer SM, Wolzt M, Ludvik B, Nansalma E,
808 Nowotny PJ, Seidinger D, Steiner S, Luger A, Artwohl M. Reduction of both number and
809 proliferative activity of human endothelial progenitor cells in obesity. *International Journal*
810 *of Obesity* 2010;**34**:687-700.
- 811 46. Fadini GP, Sartore S, Agostini C, Avogaro A. Significance of Endothelial Progenitor Cells
812 in Subjects With Diabetes. *Diabetes care* 2007;**30**:1305-1313.

- 813 47. Giannotti G, Doerries C, Mocharla Pavani S, Mueller Maja F, Bahlmann Ferdinand H,
814 Horvath T, Jiang H, Sorrentino Sajoscha A, Steenken N, Manes C, Marzilli M, Rudolph
815 KL, Lüscher Thomas F, Drexler H, Landmesser U. Impaired Endothelial Repair Capacity
816 of Early Endothelial Progenitor Cells in Prehypertension. *Hypertension* 2010;**55**:1389-
817 1397.
- 818 48. Park SK, Tao Y, Meeker JD, Harlow SD, Mukherjee B. Environmental risk score as a new
819 tool to examine multi-pollutants in epidemiologic research: an example from the NHANES
820 study using serum lipid levels. *PloS one* 2014;**9**:e98632.
- 821 49. Bobb JF, Valeri L, Claus Henn B, Christiani DC, Wright RO, Mazumdar M, Godleski JJ,
822 Coull BA. Bayesian kernel machine regression for estimating the health effects of multi-
823 pollutant mixtures. *Biostatistics* 2015;**16**:493-508.
- 824 50. Bobb JF, Henn BC, Valeri L, Coull BA. Statistical software for analyzing the health effects
825 of multiple concurrent exposures via Bayesian kernel machine regression. *Environmental*
826 *Health* 2018;**17**:1-10.
- 827 51. Ran J, Qiu H, Sun S, Tian L. Short-term effects of ambient benzene and TEX (toluene,
828 ethylbenzene, and xylene combined) on cardiorespiratory mortality in Hong Kong. *Environ*
829 *Int* 2018;**117**:91-98.
- 830 52. Xu X, Freeman NC, Dailey AB, Ilacqua VA, Kearney GD, Talbott EO. Association between
831 exposure to alkylbenzenes and cardiovascular disease among National Health and
832 Nutrition Examination Survey (NHANES) participants. *Int J Occup Environ Health*
833 2009;**15**:385-391.
- 834 53. Shim YH, Ock JW, Kim Y-J, Kim Y, Kim SY, Kang D. Association between Heavy Metals,
835 Bisphenol A, Volatile Organic Compounds and Phthalates and Metabolic Syndrome.
836 *International journal of environmental research and public health* 2019;**16**:671.
- 837 54. Penn A, Snyder CA. 1,3-Butadiene exposure and cardiovascular disease. *Mutat Res*
838 2007;**621**:42-49.
- 839 55. Capella KM, Roland K, Geldner N, Rey deCastro B, De Jesús VR, van Bemmelen D, Blount
840 BC. Ethylbenzene and styrene exposure in the United States based on urinary mandelic
841 acid and phenylglyoxylic acid: NHANES 2005–2006 and 2011–2012. *Environmental*
842 *research* 2019;**171**:101-110.
- 843 56. Mori TA, Burke V, Puddey IB, Watts GF, O'Neal DN, Best JD, Beilin LJ. Purified
844 eicosapentaenoic and docosahexaenoic acids have differential effects on serum lipids and
845 lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipidemic men. *The*
846 *American journal of clinical nutrition* 2000;**71**:1085-1094.
- 847 57. Tang W, Hemm I, Eisenbrand G. Estimation of human exposure to styrene and
848 ethylbenzene. *Toxicology* 2000;**144**:39-50.
- 849 58. Vasa M, Fichtlscherer S, Aicher A, Adler K, Urbich C, Martin H, Zeiher AM, Dimmeler S.
850 Number and migratory activity of circulating endothelial progenitor cells inversely correlate
851 with risk factors for coronary artery disease. *Circulation research* 2001;**89**:e1-e7.

- 852 59. Imanishi T, Moriwaki C, Hano T, Nishio I. Endothelial progenitor cell senescence is
853 accelerated in both experimental hypertensive rats and patients with essential
854 hypertension. *Journal of hypertension* 2005;**23**:1831-1837.
- 855 60. Li MJ, Zeng T. The deleterious effects of N,N-dimethylformamide on liver: A mini-review.
856 *Chemico-biological interactions* 2019;**298**:129-136.
- 857 61. Haberzettl P, Lee J, Duggineni D, McCracken J, Bolanowski D, O'Toole TE, Bhatnagar A,
858 Conklin DJ. Exposure to ambient air fine particulate matter prevents VEGF-induced
859 mobilization of endothelial progenitor cells from the bone marrow. *Environmental health*
860 *perspectives* 2012;**120**:848.
- 861 62. Liberda EN, Cuevas AK, Gillespie PA, Grunig G, Qu Q, Chen LC. Exposure to inhaled
862 nickel nanoparticles causes a reduction in number and function of bone marrow
863 endothelial progenitor cells. *Inhalation toxicology* 2010;**22**:95-99.
- 864 63. Brook RD, Bard RL, Kaplan MJ, Yalavarthi S, Morishita M, Dvonch JT, Wang L, Yang H-
865 y, Spino C, Mukherjee B. The effect of acute exposure to coarse particulate matter air
866 pollution in a rural location on circulating endothelial progenitor cells: results from a
867 randomized controlled study. *Inhalation toxicology* 2013;**25**:587-592.
- 868 64. DeJarnett N, Yeager R, Conklin DJ, Lee J, O'Toole TE, McCracken J, Abplanalp W,
869 Srivastava S, Riggs DW, Hamzeh I, Wagner S, Chugh A, DeFilippis A, Ciszewski T, Wyatt
870 B, Becher C, Higdon D, Ramos KS, Tollerud DJ, Myers JA, Rai SN, Shah J, Zafar N,
871 Krishnasamy SS, Prabhu SD, Bhatnagar A. Residential Proximity to Major Roadways Is
872 Associated With Increased Levels of AC133+ Circulating Angiogenic Cells. *Arterioscler*
873 *Thromb Vasc Biol* 2015.
- 874 65. Yeager R, Riggs DW, DeJarnett N, Tollerud DJ, Wilson J, Conklin DJ, O'Toole TE,
875 McCracken J, Lorkiewicz P, Xie Z, Zafar N, Krishnasamy SS, Srivastava S, Finch J, Keith
876 RJ, DeFilippis A, Rai SN, Liu G, Bhatnagar A. Association Between Residential
877 Greenness and Cardiovascular Disease Risk. *J Am Heart Assoc* 2018;**7**:e009117.
- 878 66. Chotinantakul K, Leraanansaksiri W. Hematopoietic Stem Cell Development, Niches, and
879 Signaling Pathways. *Bone Marrow Research* 2012;**2012**:16.
- 880 67. Boos CJ, Lip GYH, Blann AD. Circulating Endothelial Cells in Cardiovascular Disease.
881 *Journal of the American College of Cardiology* 2006;**48**:1538-1547.
- 882 68. Qian X, Wan Y, Wang A, Xia W, Yang Z, He Z, Xu S. Urinary metabolites of multiple
883 volatile organic compounds among general population in Wuhan, central China: Inter-day
884 reproducibility, seasonal difference, and their associations with oxidative stress
885 biomarkers. *Environmental Pollution* 2021;**289**:117913.
- 886 69. Song W, Han Q, Wan Y, Qian X, Wei M, Jiang Y, Wang Q. Repeated measurements of
887 21 urinary metabolites of volatile organic compounds and their associations with three
888 selected oxidative stress biomarkers in 0– 7-year-old healthy children from south and
889 central China. *Chemosphere* 2021:132065.

- 890 70. Mobarrez F, Antoniewicz L, Bosson JA, Kuhl J, Pisetsky DS, Lundbäck M. The effects of
891 smoking on levels of endothelial progenitor cells and microparticles in the blood of healthy
892 volunteers. *PloS one* 2014;**9**:e90314-e90314.
893
894

Figure Legends

Scheme 1. Recruitment Flow Chart.

Figure 1 Association between the urinary metabolites of VOCs and circulating levels of CACs and heat map of p-values for pair-wise associations between the urinary metabolites of VOCs and circulating levels of CACs. (A) False Discovery rate adjusted p-values for total sample (n=603). (B) False Discovery rate adjusted p-values for non-smokers (n=375). Black grids represent positive associations and blue grids represent negative associations. The intensity of color represents p-values, with darker grids indicating smaller p-values. (C) The X axis represents % difference ($\pm$ 95% confidence interval) per 2-fold increase in VOC metabolite for each CAC sub-population (CAC 1-15) in non-smokers (n=375). Generalized linear models were adjusted for age, sex, race, BMI, diabetes, hypertension, and daily PM_{2.5} levels. Models for the full sample were additionally adjusted for smoking status. Abbreviations: CEMA, N-Acetyl-S-(2-carboxyethyl)-L-cysteine; 3-HPMA, N-Acetyl-S-(3-hydroxypropyl)-L-cysteine; AAMA, N-Acetyl-S-(2-carbamoyl-ethyl)-L-cysteine; CYMA, N-Acetyl-S-(2-cyanoethyl)-L-cysteine; MU, *trans, trans*-muconic acid; DHBMA, N-Acetyl-S-(3,4-dihydroxybutyl)-L-cysteine; MHBMA3, N-Acetyl-S-(4-hydroxy-2-buten-1-yl)-L-cysteine; HPMMA, N-Acetyl-S-(3-hydroxypropyl-1-methyl)-L-cysteine; AMCC, N-Acetyl-S-(N-methylcarbamoyl)-L-cysteine; PGA, Phenylglyoxylic acid; 2HPMA, N-Acetyl-S-(2-hydroxypropyl)-L-cysteine; PHEMA, N-Acetyl-S-(1-phenyl-2-hydroxyethyl)-L-cysteine; MA, Mandelic Acid; BMA, N-Acetyl-S-(benzyl)-L-cysteine; 2MHA, 2-Methylhippuric acid; 3MHA+4MHA, 3-Methylhippuric acid + 4-Methylhippuric acid. * Represents significant association.

Figure 2. Association between Environmental Risk Scores and Circulating Angiogenic Cells in non-smokers. Environmental Risk score was calculated for each cell population as follows: 1. The urinary levels of VOC metabolites were log transformed. 2. Each log transformed VOC metabolite level was regressed against the levels of the cells separately, while adjusting for covariates. 3. ERS was calculated as the sum of the log transformed VOC metabolite levels x (regression coefficient/standard error). Mean and standard deviation of the ERS was calculated for each CAC. Values are mean $\pm$ SD of environmental risk score for each cell population.

Figure 3. Exposure-response relationships between selected CACs and VOCs in non-smokers. Non-linear relationships between MU metabolites and CACs (**A**); VOCs and CAC-4 (**B**); and VOCs and CAC-8 (**C**) were examined using restricted cubic splines. Tests for non-linearity used the likelihood ratio test. Models are adjusted for age, sex, race, BMI, diabetes, hypertension, beta-blocker use, and daily PM_{2.5} levels. P-value represents likelihood ratio test for non-linearity.

Figure 4. Association between circulating angiogenic cells and multiple VOCs in the same model (non-smokers). Values represent % difference per 2-fold increase in VOC metabolite. VOC metabolites are ordered by strength of their regression coefficients. Only significant metabolites from one-pollutant models were entered in the model. Models adjusted for age, sex, race, BMI, diabetes, hypertension, and daily PM_{2.5} levels.

Figure 5. Overall association of the VOC metabolite mixture (and 95% credible intervals) with selected CACs, when all exposures are set to a given percentile relative to median. Models (non-smokers; n=375) were adjusted for age, sex, race, BMI, diabetes, hypertension, and daily PM_{2.5} levels.

922

923 **Figure 6.** Subgroup analysis of the relationship between different CAC population with the urinary
924 metabolites of benzene (MU), 1,3-butadiene (MHBMA3), ethylbenzene/styrene (PGA), and N,N-
925 Dimethylformamide (AMCC) in non-smokers. Generalized linear models were adjusted for
926 covariates - age, sex, race, BMI, diabetes, hypertension, and daily PM_{2.5} levels, unless the
927 covariates were used for stratification. *Significant interaction between subgroups in the full
928 model.

929

930 **Scheme 2.** Gating Strategy for the Human Circulating Angiogenic Cells. Blue indicates negative
931 environmental risk score; orange indicates positive environmental risk score.

932

Supplemental Results

Supplemental Table 1. Urinary VOC metabolites and Parent Compound

VOC Structure	VOC	VOC metabolite	Common abbr.	LOD (ng/ml)
Acrolein	N-Acetyl-S-(2-carboxyethyl)-L-cysteine	CEMA	20.35
		N-Acetyl-S-(3-hydroxypropyl)-L-cysteine	3HPMA	9.12
Acrylamide	N-Acetyl-S-(2-carbamoyl)-L-cysteine	AAMA	3.03
Acrylonitrile	N-Acetyl-S-(2-cyanoethyl)-L-cysteine	CYMA	1.25
Benzene	<i>trans, trans</i> -muconic acid	MU	6.41
1,3-Butadiene	N-Acetyl-S-(3,4-dihydroxybutyl)-L-cysteine	DHBMA	6.76
		N-Acetyl-S-(4-hydroxy-2-buten-1-yl)-L-cysteine	MHBMA3	1.44
Crotonaldehyde	N-Acetyl-S-(3-hydroxypropyl-1-methyl)-L-cysteine	HPMMA	1.11
N,N-Dimethylformamide	N-Acetyl-S-(N-methylcarbamoyl)-L-cysteine	AMCC	9.87
Ethylbenzene, styrene	Phenylglyoxylic acid	PGA	6.86
Propylene oxide	N-Acetyl-S-(2-hydroxypropyl)-L-cysteine	2HPMA	3.97
Styrene, ethylbenzene	N-Acetyl-S-(1-phenyl-2-hydroxyethyl)-L-cysteine +	PHEMA	1.21
		N-Acetyl-S-(2-phenyl-2-hydroxyethyl)-L-cysteine		
		Mandelic Acid	MA	12.93
Toluene	N-Acetyl-S-(benzyl)-L-cysteine	BMA	0.45
Xylene	2-Methylhippuric acid	2MHA	1.24
		3-Methylhippuric acid + 4-Methylhippuric acid	3MHA+4MHA	6.85

Supplemental Table 2. Summary Statistics of urinary VOC metabolites in non-smokers for specific subgroups.

VOC metabolite	Male	Female	White	Black	Age <55	Age ≥55	BMI <30	BMI ≥30
n	135	240	311	43	202	173	199	176
CEMA	104.1 ± 87.6	122.4 ± 130.4	111.2 ± 102.5	136.1 ± 110.7	102.1 ± 78.4	131.8 ± 148.7	113.1 ± 132.6	118.9 ± 96.8
3HPMA	326.2 ± 269.2	350.2 ± 380.8	333.6 ± 313.3	330.3 ± 395.3	337.3 ± 325.8	346.5 ± 366.3	346.3 ± 310.9	336.1 ± 380.0
AAMA	73.4 ± 56.9	71.8 ± 64.2	71.2 ± 63.5	83.2 ± 53.5	72.2 ± 56.8	72.7 ± 66.9	77.9 ± 72.1	66.2 ± 46.3
CYMA	4.8 ± 12.3	6.1 ± 19.4	4.7 ± 15.5	12 ± 23.3	6.4 ± 17.0	4.8 ± 17.4	6.8 ± 20.6	4.4 ± 12.2
MU	125.8 ± 222.5	137.7 ± 209.4	146 ± 228.7	62.2 ± 52.1	126.0 ± 208.3	142.0 ± 220.8	134.8 ± 229.1	131.7 ± 196.2
DHBMA	348.7 ± 182.2	356.4 ± 172.6	363.6 ± 181.3	311.8 ± 148.3	328.0 ± 157.2	383.5 ± 191.6	355.0 ± 166.6	352.1 ± 186.3
MHBMA3	8.4 ± 8.6	9.5 ± 8	9.3 ± 8.6	8.2 ± 6.1	9.2 ± 7.9	9.0 ± 8.6	10.2 ± 9.6	7.9 ± 6.1
HPMMA	286.1 ± 271.3	321.5 ± 324.1	305.1 ± 265.4	347.3 ± 529.9	275.4 ± 241.8	328.6 ± 267.7	315.1 ± 292.7	282.8 ± 203.8
AMCC	140 ± 99.4	171.9 ± 125.1	169.3 ± 121.1	118.5 ± 74.2	143.2 ± 104.3	180.5 ± 128.3	165.7 ± 119.9	154.5 ± 114.4
PGA	202.2 ± 117.2	239.1 ± 157.9	232.2 ± 151.8	196.3 ± 105	215.5 ± 149.0	238.0 ± 140.9	226.8 ± 154.1	224.9 ± 135.7
2HPMA	67.7 ± 160.1	53.1 ± 95.8	60.1 ± 131.4	40.8 ± 31.8	58.1 ± 116.8	58.6 ± 130.0	67.1 ± 147.8	48.4 ± 86.0
PHEMA	2.3 ± 5.4	2.2 ± 3	2.3 ± 4.4	1.7 ± 1.2	2.1 ± 3.9	2.3 ± 4.2	2.2 ± 3.9	2.2 ± 4.2
MA	206.3 ± 124.1	247.7 ± 183.3	243.7 ± 175.6	177.8 ± 91.8	210.7 ± 139.5	258.7 ± 188.7	231.4 ± 156.0	234.5 ± 176.0
BMA	10.7 ± 12.4	12 ± 11.9	11.4 ± 12.1	11.6 ± 11.8	10.5 ± 11.9	12.7 ± 12.2	12.2 ± 12.8	10.7 ± 11.1
2MHA	26.3 ± 37.1	36.5 ± 89.8	33.8 ± 78.7	25.5 ± 32.6	27.6 ± 50.4	32.9 ± 56.7	37.9 ± 63.7	21.2 ± 36.8
3MHA+4MHA	189 ± 313.1	220.5 ± 454.3	213 ± 436	193.8 ± 205.9	179.8 ± 310.6	212.5 ± 293.9	227.4 ± 367.2	158.4 ± 204.2

Values represent Mean ± SD. Units: µg/g creatinine. Bold values represent significant difference between specific subgroups, based on T-test of log-transformed VOC metabolites.

Supplemental Table 2 continued. Summary Statistics of urinary VOC metabolites in non-smokers for specific subgroups.

VOC metabolite	Non-Diabetic	Diabetic	Normotensive	Hypertensive	Low PM _{2.5}	High PM _{2.5}
n	310	65	219	156	189	186
CEMA	116.8 ± 123.3	111.2 ± 81	104.7 ± 85.1	131.4 ± 149.8	117.0 ± 92.4	114.6 ± 137.9
3HPMA	338.7 ± 341.3	355 ± 362.4	327.9 ± 315.8	360.6 ± 381.7	371.4 ± 411.7	311.2 ± 257.0
AAMA	74.6 ± 64.3	62.2 ± 45.5	70.7 ± 55.6	74.9 ± 69.3	65.0 ± 41.6	80.0 ± 76.1
CYMA	6.1 ± 18.5	3.6 ± 8.7	5.7 ± 15.9	5.6 ± 18.9	4.4 ± 12.3	7.0 ± 21.0
MU	128.1 ± 213.7	158.4 ± 215.3	127.5 ± 227.6	141.6 ± 193.7	142.7 ± 257.3	123.9 ± 158.5
DHBMA	354.3 ± 172.8	350.4 ± 191.2	347.4 ± 164.4	362.4 ± 191.2	368.6 ± 182.0	338.5 ± 168.6
MHBMA3	9.3 ± 8.6	8.3 ± 6.2	8.9 ± 7.7	9.5 ± 8.9	9.1 ± 8.4	9.2 ± 8.1
HPMMA	300.9 ± 260.8	346 ± 466.9	277.8 ± 228	352.1 ± 387.2	308.9 ± 278.3	290.9 ± 229.5
AMCC	157.3 ± 108.6	175.1 ± 152.4	154.8 ± 109.2	168.3 ± 127.8	153.5 ± 102.8	167.4 ± 130.4
PGA	219.3 ± 143.1	257.2 ± 154	222.7 ± 156.8	230.3 ± 128.6	208.3 ± 133.0	243.7 ± 155.6
2HPMA	62 ± 132.5	40.9 ± 55.8	66.1 ± 137	47.4 ± 99.3	64.8 ± 144.2	51.8 ± 96.5
PHEMA	2.3 ± 4.4	1.8 ± 1.9	2.3 ± 4.6	2.1 ± 3.2	2.1 ± 3.6	2.3 ± 4.5
MA	228.5 ± 155.5	253.4 ± 206.9	223.9 ± 154.4	245.3 ± 179.6	217.1 ± 146.2	248.9 ± 182.1
BMA	12 ± 12.7	9.4 ± 8.1	11.7 ± 12.7	11.3 ± 11.1	10.8 ± 11.4	12.3 ± 12.7
2MHA	35 ± 80	22.5 ± 46.6	37.4 ± 91.6	26.5 ± 43.2	32.8 ± 64.7	27.3 ± 38.8
3MHA+4MHA	223.7 ± 445.8	140.2 ± 115.9	226.4 ± 480	185.2 ± 282.4	211.2 ± 368.4	178.4 ± 218.4

Values represent Mean ± SD. Units: µg/g creatinine. Bold values represent significant difference between specific subgroups, based on T-test of log-transformed VOC metabolites. Low PM_{2.5} ranges from 1.2-7.8 µg/m³. High PM_{2.5} ranges from 8.0-17.7 µg/m³.

Supplemental Figure 1. Pearson correlation coefficients between log-transformed urinary VOC metabolites and ambient pollutant and meteorological data (non-smokers; n=375).

Supplemental Figure 2. Heat map of pair-wise associations between the urinary metabolites of VOCs and circulating levels of CACs. False Discovery rate adjusted p-values. Generalized linear models (non-smokers; n=375) were adjusted for age, sex, race, BMI, diabetes, hypertension and: daily PM_{2.5} + Temperature (A); daily PM_{2.5} + Humidity (B); Ozone + Temperature (C); Ozone + Humidity (D). Black grids represent positive associations and blue grids represent negative associations. The intensity of colors represent p-values, with darker grids indicating smaller p-values.